FirsthandHealth
medRxiv PreprintsInternational19 November 2026

Sputum quality and diagnostic outcomes of GeneXpert MTB/RIF assay among adults with presumed tuberculosis in two district hospitals in Ghana: A retrospective cross-sectional study.

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Background: Tuberculosis remains a major public health challenge in Ghana, where GeneXpert MTB/RIF serves as a first-line diagnostic tool. However, uncertainties about this method persist regarding specimen quality and the clinical significance of indeterminate rifampicin susceptibility results. Methods: We conducted a retrospective cross-sectional study of samples from 3,977 presumptive TB patients tested either at HopeXchange Medical Center (Kumasi) or Keta Municipal Hospital between January 2020 and December 2024. Demographic data, sputum macroscopic appearance, and GeneXpert results were a
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.